Digital oral presentations 2020
- DOP01 Exclusive enteral nutrition for the treatment of adult Crohn’s disease
- DOP02 The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers
- DOP03 The impact of elemental diet on the human gut microbial structure and intestinal metabolites
- DOP04 Matching between donors and patients in faecal microbiota transplantation is important for long-term maintenance on ulcerative colitis
- DOP05 Perioperative Dietary Therapy in inflammatory bowel disease
- DOP06 Non-invasive identification of adherent-invasive
E. coli in patients with Crohn’s disease - DOP07 Long-term results of 4.5 years of faecal microbiota transplantation for treatment of refractory ulcerative colitis
- DOP08 Deep remission in paediatric Crohn’s disease is associated with increased abundance of dialister species and increased valerate
- DOP09 IgG responses to multiple bacterial flagellins identify a subgroup of paediatric therapy-naive Crohn’s disease patients with increased microbiota-specific T-cell reactivity
- DOP10 Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy
- DOP11 Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn’s disease
- DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension
- DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial
- DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease
- DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease
- DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2
- DOP17 Identification of biomarkers and mechanistic insight for upadacitinib in ulcerative colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study
- DOP18 Impact of adherence to anti-tumour necrosis factor therapy on clinical outcomes in Crohn’s disease: A nationwide population-based study
- DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months
- DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine
- DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study
- DOP22 Certification of integral care IBD Units: Evaluation of a certification program (CUE)
- DOP23 Endoscopic evaluation at 1 month after ileocolic resection for Crohn’s disease predicts postoperative recurrence and is safe
- DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial
- DOP25 Medication use and comorbidities among elderly when compared with younger patients with inflammatory bowel disease in the TARGET-IBD cohort
- DOP26 Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease
- DOP27 Transanal minimally invasive surgery (TAMIS): A novel approach for treatment of pouch failure
- DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s disease: A pilot serum proteomic analysis of the PANTS cohort
- DOP29 Elevation of a novel blood-based gene signature in a severe Crohn’s disease (CD) subtype preceding surgery defines and predicts a post-surgical decrease in pro-inflammatory pathway activation
- DOP30 Multi-‘omics profiling in patients with quiescent inflammatory bowel disease identifies biomarkers predicting relapse
- DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches
- DOP32 Clinical and molecular characterisation of patients with durable response to ustekinumab induction therapy: Results from the UNIFI phase 3 studies in moderate-to-severe ulcerative colitis
- DOP33 Stratification of patients for treatment with adalimumab by a combination of immune-profiling and in vivo efficacy studies in a novel mouse model of ulcerative colitis
- DOP34 Transplantation of human intestine into the mouse: A novel platform for study of inflammatory enterocutaneous fistulas
- DOP35 Monitoring of mucosal T cells subsets under biotherapies in IBD: responders exhibit a phenotype similar to healthy controls
- DOP36 Family-specific host genetic and gut microbial signatures have a beneficial role in early identification of familial inflammatory bowel diseases
- DOP37 Neoplastic lesions outside diseased area in inflammatory bowel disease patients: A national cohort study
- DOP38 Prevalence of fatigue in a severe inflammatory bowel disease cohort highly exposed to biologics
- DOP39 The first prospective, multicentre, randomised controlled trial on discontinuation of infliximab in ulcerative colitis in remission; endoscopic normalisation does not guarantee successful withdrawal
- DOP40 Does levels of concerns and expectations predict IBD disease status?
- DOP41 Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study
- DOP42 Impact of discontinuing thiopurines at anti-TNF initiation in inflammatory bowel disease: A nationwide Danish cohort study
- DOP43 The risk of extra-intestinal cancer in inflammatory bowel disease (IBD): A systematic review and meta-analysis of population-based cohort studies
- DOP44 Cancer risk in a high-incidence inflammatory bowel disease population: a Faroese IBD cohort study
- DOP45 Increased prevalence but not incidence of myocardial infarction and stroke in patients with inflammatory bowel diseases in Quebec in 1996–2015
- DOP46 Impact of a genetic burden on familial aggregation of inflammatory bowel disease
- DOP47 The changing pattern of inflammatory bowel disease incidence in Northern France: A continuing increase in the young women (1988–2014)
- DOP48 Gene expression landscape of epithelial monolayer in inflammatory bowel disease
- DOP49 Quantitative proteomics analysis of macrophages from Crohn’s disease patients and infected with adherent-invasive
Escherichia coli - DOP50 The landscape of somatic mutations in non-neoplastic IBD-affected colon
- DOP51 Investigation on the role of Par4-associated cell polarity and associated barrier defects in inflammatory bowel diseases
- DOP52 The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s disease or ulcerative colitis reflects the respective disease
- DOP53 PTPN2 and TiO2 in the pathogenesis of inflammatory bowel disease
- DOP54 Integrated network analysis using patient-specific single-nucleotide polymorphism profiles uncovers new pathways involved in ulcerative colitis pathogenesis
Digital oral presentations: DOP Session 7 - Comparing outcomes of biologic treatments for IBD (2020) (9)
- DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
- DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension
- DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case–control study
- DOP58 Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
- DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
- DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP)
- DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
- DOP62 Morbidity after primary ileocecal resection for Crohn’s disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre
- DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial
- DOP64 Discovery of highly selective small-molecule oral inhibitors of integrin α4β7 for the treatment of inflammatory bowel diseases
- DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity
- DOP66 A CEACAM5 small peptide restores the suppressive activity of CD8 + T cells in patients with Crohn’s disease
- DOP67 CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signalling pathway
- DOP68 Thiomyristoyl ameliorates colitis by blocking the differentiation of Th17 cells via STAT3/IL-6 signal pathway
- DOP69 Tofacitinib in ulcerative colitis: Early ‘real-world’ experience from four UK tertiary centres
- DOP70 High-dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in inflammatory bowel disease
- DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study
- DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study
- DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
- DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study
- DOP75 Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study
- DOP76 Corticosteroid sparing effects of ustekinumab therapy for ulcerative colitis through 2 years: UNIFI long-term extension
- DOP77 Ustekinumab is associated with better effectiveness outcomes when compared with vedolizumab in Crohn’s disease patients with prior anti-TNF failure: comparative effectiveness study from the ICC Registry
- DOP78 Intestinal surgery rates in ulcerative colitis and Crohn’s disease in the era of biologics: A Danish Nationwide Register Study from 2003 to 2016
- DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study
- DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study
- DOP81 Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE sustain
- DOP82 Macrophages in Crohn’s disease mesentery are predominantly inflammatory and produce calprotectin
- DOP83 Intestinal fibrosis in Crohn’s disease patients is marked by up-regulation of innate immune cells and mucosal B cells
- DOP84 Crohn’s disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remission
- DOP85 The role of fibroblasts in the pathogenesis of Crohn’s disease-associated fistulas and in mesenchymal stem cell therapy
- DOP86 An IFN-STAT1-MLKL axis drives programmed necrosis of Paneth cells in Crohn’s ileitis
- DOP87 SUCNR1 a novel key protagonist in fistula development
- DOP88 Visceral fat area correlates well with anti-TNFα drug levels and secondary loss of response in Crohn’s disease patients
- DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease
- DOP90 The role of Nlrp9b, a novel NLR member in regulating experimental colitis